TNFRSF10B, a Therapeutic Target for Oral Squamous Cell Carcinoma Through Integrated Bioinformatics and Preliminary Experiments.

Technol Cancer Res Treat · 2026 · PMC12954003 · PMID 41769784

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

extremely significantP < .001actually significant

Specifically, OAS3, MMP1, TMSB10, PFN2, WARS1, TRIB2, GBP1, and TNFRSF10B exhibited extremely significant overexpression with adjusted P value (adj.) P < .001, while MBNL3 showed a significant difference in expression (compared with normal tissues) with an adj.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.